Nonprofit medical research organization the Usona Institute shared the results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for 104 adults with Major Depressive Disorder (MDD,) providing further evidence of the psychedelic’s antidepressant capabilities.
Led by a research team from institutions including Yale, Johns Hopkins, NYU Langone and San Francisco Veterans Affairs Medical Center and published in the Journal of the American Medical Association (JAMA,) outcomes reveal that psilocybin was well-tolerated and elicited fast, solid and long-lasting efficacy results.
The reportedly largest Phase 2, randomized, double-blind, placebo-controlled study of a single psilocybin dose to treat MDD followed participants for six weeks and took place between Dec. 2019 and June 2022.
The 25mg dose paired with psychological support was associated with a significant reduction in depressive symptoms at day …